title: Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity.
abstract: In the present study, the adjuvant capacity of oligomannose-coated liposomes (OMLs) was evaluated in mice, and an OML-based vaccine was shown to induce effective anti-tumor immunity. C57BL/6 mice were immunized subcutaneously with OML-encased ovalbumin (OVA) and challenged with OVA-expressing E.G7-OVA tumor cells. All mice that received OVA in OMLs completely rejected the E.G7-OVA tumor. Spleen cells from the immunized mice showed strong cytotoxic activity against E.G7-OVA cells, but not against the parental EL4 cells. The therapeutic efficacy of OML-encased OVA against established E.G7-OVA tumors was then investigated. When the tumor mass became palpable (8-10 mm in length), the mice were treated with a single injection of 1 microg of OML-encased OVA. Tumor growth was reduced significantly in mice treated with OML-encased OVA and tumors were completely eliminated in about 40% of these mice. Similar results were obtained using EL4 tumors, with the EL4 cell lysate used as an antigen. These results indicate that an OML-based vaccine with an encased tumor antigen might be useful clinically to raise an effective immune response against a tumor.
authors.affiliation: Department of Applied Biochemistry, Tokai University, Hiratsuka, Kanagawa 259-1292, Japan. naoyaki@keyaki.cc.u-tokai.ac.jp
authors.forename: Naoya
authors.initials: N
authors.lastname: Kojima
authors.forename: Le
authors.initials: L
authors.lastname: Biao
authors.forename: Tomoko
authors.initials: T
authors.lastname: Nakayama
authors.forename: Mariko
authors.initials: M
authors.lastname: Ishii
authors.forename: Yuzuru
authors.initials: Y
authors.lastname: Ikehara
authors.forename: Kunio
authors.initials: K
authors.lastname: Tsujimura
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000737:chemistry; D000818:Animals; D000941:Antigens / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D045744:Cell Line, Tumor; D002626:Chemistry, Pharmaceutical; D004339:Drug Compounding; D007279:Injections, Subcutaneous; D008055:Lipids / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D008081:Liposomes; D008198:Lymph Nodes / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D013678:Technology, Pharmaceutical / Q000379:methods; D013945:Thymoma / Q000276:immunology / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D013953:Thymus Neoplasms / Q000276:immunology / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D013997:Time Factors; D014312:Trisaccharides / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000941:Antigens; D019496:Cancer Vaccines; D008055:Lipids; D008081:Liposomes; D014312:Trisaccharides; C023872:mannotriose; D010047:Ovalbumin